RANDOMISED CONTROLLED STUDY ON EARLY RENSPONSE TO COMBINED ANTIVIRAL THERAPY IN CHRONIC H EPATITIS C PATIENTS GENOTIPE 2 AND 3 WITH HCV-RNA NEGATIVE WEEK 4

INTERVENTION: Trade Name: PEGINTRON*SC 1PEN 80MCG+1AGO+2 Pharmaceutical Form: Powder and solvent for suspension for injection INN or Proposed INN: Peginterferon alfa‐2b CAS Number: 215647‐85‐1 Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 80‐ Trade Name: REBETOL*84CPS 200MG Pharmaceutical Form: Capsule, soft INN or Proposed INN: Ribavirin CAS Number: 36791‐04‐5 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 200‐ CONDITION: SOSTAINED BIOCHEMICAL AND VIROLOGICAL RESPONSE TO COMBINADET THERAPY PEGILATED RIBAVIRIN IN CHRONIC HEPATITIES PATIENTS G 2 AND 3 ; MedDRA version: 9.1 Level: LLT Classification code 10019663 Term: Hepatic failure PRIMARY OUTCOME: Main Objective: Primary end point(s): Secondary Objective: INCLUSION CRITERIA: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18‐64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range